Abiraterone acetate: redefining hormone treatment for advanced prostate cancer

Download Type: Adobe PDF

In this article Carmel J. Pezaro, Deborah Mukherji and Johann S. De Bono review the preclinical discovery and clinical development of abiraterone acetate and outline the strategy of parallel translational research.

Abiraterone acetate is a rationally designed CYP17 inhibitor that has proved to be an effective and well-tolerated oral treatment for men with advanced castration-resistant prostate cancer. It has recently received FDA approval for use following docetaxel chemotherapy and there are ongoing clinical and translational studies that are exploring the best strategies for clinical use.


Share this download

More services